News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • JD.com shares have been under pressure amid slowing growth.
  • The stock trades at 18.4x PE and roughly 1.19x PB.
  • JD.com stock yields about 3.6%.
  • Technical indicators show oversold readings.
  • Proposed trade is a disciplined 45-trading-day long with entry, stop, and target levels.
  • The idea highlights balance-sheet optionality the market appears to be ignoring.

Latest Articles

Appian Announces Second Quarter 2026 Financial Results

Appian Announces Second Quarter 2026 Financial Results

Appian Corporation announced its financial results for Q2 2026, showing 19% year-over-year total revenue growth to $203.3 million driven by increased cloud subscriptions and professional services. The company improved its GAAP operating loss compared to the prior year and recorded a significant increase in non-GAAP operating income and adjusted EBI…

Lifetime Brands, Inc. Reports Second Quarter 2026 Financial Results

Lifetime Brands, Inc. Reports Second Quarter 2026 Financial Results

Lifetime Brands, Inc. announced its financial results for Q2 2026, reporting net sales growth of 7.4% year-over-year and significant earnings improvement driven by a $40.1 million tariff refund. The company repaid $40 million in term debt, showed robust growth in warehouse club and e-commerce channels, and reaffirmed net sales guidance while raisin…

Safe Pro Group Receives $780,000 Purchase Order for Department of War Package of Edge AI-Powered Threat Mapping and Blue UAS Drones

Safe Pro Group Receives $780,000 Purchase Order for Department of War Package of Edge AI-Powered Threat Mapping and Blue UAS Drones

Safe Pro Group Inc., a Nasdaq-listed developer of AI-enabled defense and security solutions, announced a $780,000 purchase order from a new Department of War Prime Contractor. The order includes edge AI threat detection technology and Blue UAS drones, with work starting in Q3 2026 and expected completion in Q1 2027. This award marks the fifth recen…

Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates

Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates

Iovance Biotherapeutics reported a record second quarter 2026 revenue of approximately $99 million, a 66% year-over-year increase, driven primarily by strong demand for its commercial product Amtagvi in the U.S. The company improved its gross margin to 56% and is reviewing its full-year 2026 revenue guidance upwards. Clinical progress includes FDA …

Gilat Demonstrates Breakthrough AI-Based Interference Detection and Cancellation Technology for Satellite Links

Gilat Demonstrates Breakthrough AI-Based Interference Detection and Cancellation Technology for Satellite Links

Gilat Satellite Networks announced a successful demonstration of its breakthrough AI-based interference detection and cancellation technology for satellite links. This patent-pending solution significantly improves interference mitigation by up to 10 times compared to conventional methods, maintaining signal integrity even under challenging interfe…

Resolute Holdings Reports Second Quarter 2026 Results

Resolute Holdings Reports Second Quarter 2026 Results

Resolute Holdings Management, Inc. reported second-quarter fiscal 2026 financial results showing a net loss per share of $1.53 under GAAP, primarily impacted by consolidation of GPGI Holdings. However, non-GAAP fee-related earnings per share increased significantly to $0.69, driven by new and expanded management agreements. The company repurchased …

Commerce Announces Second Quarter 2026 Financial Results

Commerce Announces Second Quarter 2026 Financial Results

Commerce.com, Inc. announced its Q2 2026 financial results, posting total revenue of $84.5 million, a slight increase YoY, and a 14% growth in Gross Merchandise Volume. For the second consecutive quarter, the company reported positive GAAP net income of $1.1 million and improved non-GAAP operating income and adjusted EBITDA. Investments continue in…

Tilray Brands Expands THC Beverage Innovation with the Launch of Mollo Lite Blackberry Lemon Seltzer Multi-Pack

Tilray Brands Expands THC Beverage Innovation with the Launch of Mollo Lite Blackberry Lemon Seltzer Multi-Pack

Tilray Brands, Inc. announced the launch of the Mollo Lite Blackberry Lemon Seltzers 4-Pack, introducing its first light THC beverage multi-pack in Canada. This low-dose, sessionable cannabis beverage format targets adult consumers seeking approachable potency with refreshing flavor and convenient multi-pack options. The product enhances Tilray's l…

Gogo Announces Second Quarter Results

Gogo Announces Second Quarter Results

Gogo Inc., a leading provider of broadband connectivity solutions for business and military aviation markets, announced Q2 2026 results with total revenue of $222.8 million, a 1% decrease year-over-year. Military/government service revenue grew 40% year-over-year and 20% sequentially, marking a record quarter. Net loss was $2.0 million with adjuste…

Harrow Acquires Global Rights to TYRVAYA®,  the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

Harrow, Inc. announced the acquisition of TYRVAYA®, a novel nasal spray treatment for dry eye disease, from Viatris Inc., aiming to enhance its ophthalmic product portfolio. TYRVAYA offers an alternative to eye drops with a unique delivery method and complements Harrow's existing products, expanding treatment options for dry eye sufferers. The acqu…

CareCloud Reports Second Quarter 2026 Results

CareCloud Reports Second Quarter 2026 Results

CareCloud, Inc. announced its Q2 2026 financial results showing 16% revenue growth to $31.9 million and sustained profitability with a GAAP net income of $1.1 million. The company expanded its product portfolio by acquiring Empower Healthcare & Compliance Partners, entering the compliance and audit-defense market. CareCloud reaffirmed its full-year…

GPGI Reports Second Quarter 2026 Results

GPGI Reports Second Quarter 2026 Results

GPGI, Inc. announced its Q2 2026 financial results, showing a 4% decrease in pro forma adjusted net sales to $473.2 million and a 13% decline in pro forma adjusted EBITDA to $113.9 million, with margins down 230 basis points. Notably, CompoSecure delivered record performance driven by ROS-enabled improvements, while Husky met expectations amid mark…

Macerich Announces Proposed Offering of Exchangeable Senior Notes

Macerich Announces Proposed Offering of Exchangeable Senior Notes

The Macerich Company announced its operating partnership's intent to offer $600 million in exchangeable senior notes due 2031 through a private placement targeting qualified institutional buyers. The notes offer semi-annual interest and will be guaranteed by Macerich on a senior unsecured basis. Proceeds will be used to refinance existing secured d…

Ligand Reports Second Quarter 2026 Financial Results

Ligand Reports Second Quarter 2026 Financial Results

Ligand Pharmaceuticals reported robust second quarter 2026 financial results with a 32% year-over-year growth in royalty revenue, raising the low end of its adjusted EPS guidance while maintaining revenue guidance. The company completed a $700 million zero-interest convertible debt financing and finalized the acquisition of XOMA Royalty, significan…

Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update

Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update

Generate Biomedicines Inc. reported continued progress in its clinical programs and platform advancements during Q2 2026. The company is advancing its Phase 3 SOLAIRIA studies for GB-0895 in severe asthma, enrolling patients globally, and will present Phase 1b data for GB-0895 in COPD at the ERS Congress. It also dosed the first cohort in a Phase 1…